An engineered IL-2 reprogrammed for anti-tumor therapy using a semi-synthetic organism

Jerod L. Ptacin1✉, Carolina E. Caffaro1, Lina Ma1, Kristine M. San Jose Gall1, Hans R. Aerni1✉, Nicole V. Acuff1, Rob W. Herman1, Yelena Pavlova1, Michael J. Pena1, David B. Chen1, Lilja K. Koriazova1, Laura K. Shawver1, Ingrid B. Joseph1 & Marcos E. Milla1✉

The implementation of applied engineering principles to create synthetic biological systems promises to revolutionize medicine, but application of fundamentally redesigned organisms has thus far not impacted practical drug development. Here we utilize an engineered microbial organism with a six-letter semi-synthetic DNA code to generate a library of site-specific, click chemistry compatible amino acid substitutions in the human cytokine IL-2. Targeted covalent modification of IL-2 variants with PEG polymers and screening identifies compounds with distinct IL-2 receptor specificities and improved pharmacological properties. One variant, termed THOR-707, selectively engages the IL-2 receptor beta/gamma complex without engagement of the IL-2 receptor alpha. In mice, administration of THOR-707 results in large-scale activation and amplification of CD8+ T cells and NK cells, without Treg expansion characteristic of IL-2. In syngeneic B16-F10 tumor-bearing mice, THOR-707 enhances drug accumulation in the tumor tissue, stimulates tumor-infiltrating CD8+ T and NK cells, and leads to a dose-dependent reduction of tumor growth. These results support further characterization of the immune modulatory, anti-tumor properties of THOR-707 and represent a fundamental advance in the application of synthetic biology to medicine, leveraging engineered semi-synthetic organisms as cellular factories to facilitate discovery and production of differentiated classes of chemically modified biologics.
The recombinant human cytokine interleukin-2 (rhIL-2, or aldesleukin), originally approved for renal cell carcinoma in 1992, pioneered the era of immune oncology. Despite complete and durable responses, the widespread use of rhIL-2 therapy for oncology has been limited due to its severe toxicity. The toxic side-effects of rhIL-2 therapy stem from two distinct and fundamental characteristics of the drug: (1) short half-life, requiring high doses for activity and (2) the engagement of the IL-2 receptor alpha subunit (IL-2Ra, or CD25) on off-target cells. Therefore, engineering rhIL-2 to improve its half-life and decrease IL-2Ra engagement may produce a safer and more efficacious drug.

IL-2 functions as a lymphocyte growth and stimulatory factor, signaling via activation of the heterodimeric IL-2 receptor complex consisting of two subunits, IL-2 receptor β (CD122) and the common γ receptor subunit (CD132), or the heterotrimeric IL-2 receptor complex that includes IL-2 Ra (CD25). IL-2 activation of the IL-2 Rβγ complex induces proliferative and activation signals through STAT5 phosphorylation that drive effector T and natural killer (NK) cell expansion and tumor clearance. In addition, the IL-2 Rαβ and γ subunits, certain cell types express the IL-2 Ra subunit, which functions to increase affinity and capture of IL-2 by the signaling complex. The expression of the IL-2 Ra subunit on CD4+ regulatory T cells (Tregs) results in the preferential stimulation of these immunosuppressive cell types and is reported to limit the stimulatory effects of IL-2 on effector populations needed for anti-tumor responses.

In addition, IL-2 Ra is expressed on vascular endothelial tissue, type 2 innate lymphoid cells and eosinophils. Stimulation of these off-target cell types via aldesleukin treatment is thought to induce a constellation of severe adverse manifestations associated with vascular leak syndrome (VLS), an often fatal condition that results from increased capillary permeability. Therefore, significant ongoing efforts aim to develop modified rhIL-2 variants that mediate potent IL-2 Rβγ stimulation of CD8 effector T and NK cells, yet reduce IL-2 Ra binding to mitigate Treg-mediated suppression and off-target toxicity.

We applied a synthetic biology platform to engineer an improved and differentiated version of rhIL-2. This technology allows the facile design and production of proteins modified with non-natural amino acids at specific sites, enabling targeted bioconjugation for modulation of pharmacology and drug properties. The technology relies on an E. coli BL21(DE3)-based strain engineered to harbor a synthetic, orthogonal DNA base pair formed between the synthetic nucleosides dNaM and dTPT3 (Fig. 1a), herein referred to as X and Y, respectively. The X–Y base pairs work in concert with the native A–T/G–C base pairs to expand the coding capacity of DNA, allowing the formation of unique and orthogonal codons in mRNA and the cognate anticodons in orthogonal tRNAs required to decode them. The new codons are matched with non-natural amino acids via an orthogonal tRNA synthetase (PyRS) from M. bakeri, which exclusively aminoacylates the pytT RNA with the click-chemistry compatible, azide-containing non-natural amino acid (nAA) N6-(2-azidoethoxy)-carbonyl-l-lysine (hereafter referred to as AzK). In concert with the native translational machinery, the engineered cell utilizes the AzK-charged pytT tRNA (GYU) to decode the cognate AXC codon (Fig. 1b), allowing the production of modified proteins with site-specific incorporation of AzK.

Using this semi-synthetic microbial platform, we generated a library of site-specific rhIL-2 variants by substitution of single amino acid residues comprising the IL-2/IL-2Ra interface with AzK. Azide-modified variants were then covalently bioconjugated with linear polyethylene glycol (PEG) moieties using strain-promoted azide–alkyne click chemistry (SPAAC, Fig. 1c) and screened using recombinant cells in vitro to identify compounds that retain IL-2 Rβγ potency but demonstrate reduced IL-2 Ra engagement, a “not-alpha” pharmacological phenotype. This screening identified THOR-707 (also termed SAR-444245), a pegylated rhIL-2 variant that shows comparable potency relative to unmodified rhIL-2 at the IL-2 Rβγ, but dramatic and specific reduction of IL-2 Ra engagement. In primary human lymphocytes, THOR-707 potently stimulated pSTAT5 signaling in CD8+ T and NK cells, yet compared to rhIL-2 showed a significant reduction in potency for pSTAT5 induction in Treg cells.

In naive mice, THOR-707 demonstrated increased half-life and exposure relative to rhIL-2. THOR-707 administration stimulated the expansion of peripheral CD8+ T and NK cell counts without significantly expanding CD4+ Treg cells, even at doses expected to drive near-maximal receptor occupancy. In C57BL/6 mice bearing B16-F10 tumors, THOR-707 showed increased intratumoral distribution and retention and stimulated a significant elevation in infiltrating CD8+ T and NK cells and dose-dependent reduction in tumor growth. Together, these results suggest that site-specific bioconjugation of rhIL-2 with PEG to generate THOR-707 reprograms the pharmacological activity of this cytokine, modulating both half-life and receptor engagement profiles to create a potent CD8+ effector T and NK cell activator with reduced CD4+ Treg bias.

Results

Identification of pegylated IL-2 compounds that mediate potent IL-2 Rβγ agonism with reduced IL-2 Ra engagement. Structures of the IL-2/heterotrimeric receptor signaling complex demonstrated that the IL-2 Ra and βγ subunits engage IL-2 from opposite sides and that the α subunit engages IL-2 independently of the IL-2 βγ interfaces. We hypothesized that replacement of IL-2 residues in or near the IL-2 Ra interface with nAAs and pegylation of these sites could produce a modified IL-2 that reduces IL-2 Ra interactions while maintaining interactions with IL-2 Rβγ (Fig. 2a, b). Ten IL-2 residues hypothesized to affect IL-2 interactions with IL-2Ra after pegylation were selected for production and functional analysis: K35, R38, T41, F42, K43, Y45, E65, P62, P65 and V69. Compounds with the selected AzK-modified sites were expressed as inclusion bodies in our E. coli-based semi-synthetic organism, purified and refolded (Methods). The refolded AzK-modified IL-2 variants were then pegylated site-specifically at the AzK residue using DBCO-functionalized mPEG molecules, which allow covalent attachment of mPEG moieties to the AzK via copper-free click chemistry (Fig. 1c and “Methods” section).

Candidate compounds were screened for selective IL-2 receptor agonist activity using a recombinant human cell-based reporter system that expresses the IL-2 receptor β (IL-2Rβ) and γ (IL-2Rγ) subunits each fused to half of the split reporter enzyme β-galactosidase and a second cell line that additionally expresses the IL-2Ra subunit (Discover, Fremont CA, Supplementary Fig. 1A). Parallel testing with these cell lines allowed assessment of PEG-IL-2 variant activation of the IL-2 receptor βγ as well as the trimeric βγ complex. The EC50 (potency) of each test article and comparison of dose–response curve profiles between IL-2 Ra positive and negative cell types allowed determination of the contribution of IL-2 Ra to the observed activity.

From the screen, multiple pegylated IL-2 variants were identified that retained potent IL-2Rβγ agonist activity with reduced interaction with IL-2Ra: notably, variants replacing positions Glu62 and Pro65 (Fig. 3a and Supplementary Table 1, Supplementary Fig. 1). Initial studies demonstrated similar receptor specificity, but increased half-life and pharmacodynamic responses with 30 kDa mPEG modification in mice (not shown).
and therefore the 30 kDa mPEG was selected for further screening and development. The IL-2 compound with residue Pro65 replaced with AzK and pegylated with a 30 kDa mPEG, hereafter referred to as THOR-707, exhibited higher expression levels of the precursor protein and was selected for further characterization. In the IL-2Rβγ assay, the EC50 of the THOR-707 compound was moderately reduced in potency compared to rhIL-2 (~4-fold, 120 vs 32 ng/mL, respectively, Supplementary Fig. 1). However, in the IL-2Rαβγ assay, the potency of THOR-707 was strongly reduced relative to rhIL-2 (~47-fold, 33 vs 0.7 ng/mL, respectively, Supplementary Fig. 1).

Biochemical characterization of THOR-707 interactions with IL-2 receptor α and β subunits using SPR. The biochemical interactions of THOR-707 with human IL-2 receptor subunits were measured using surface plasmon resonance (SPR). The extracellular portions of the human IL-2 receptor subunits α and β were

---

**Fig. 1 Overview of the X–Y expanded genetic code technology.**

**a.** Structures of the natural base pairs A-T (left) and G-C (center) and the X–Y synthetic DNA base pair (right, highlighted in orange/blue). Rather than utilizing hydrogen bond donors and acceptors between pairs (dotted lines), the synthetic base pair formed between NaM (X) and TPT3 (Y) utilizes non-Watson-Crick mode of pairing that is based predominantly on hydrophobic packing interactions. **b.** Schematic of the semi-synthetic organism (SSO) platform based on *E. coli* BL21(DE3). The organism constitutively expresses a variant of the PtNTT2 nucleotide transporter (green)\(^1\), which mediates the transport of X and Y nucleoside triphosphates from the growth medium into the cytoplasm for DNA and RNA synthesis. X–Y containing DNA sequences are transcribed into mRNA and tRNA that contain the codon (AXC) and anticodon sequences (GYU), respectively. The orthogonal tRNA synthetase PyrRS from *M. barkeri* (blue) specifically recognizes the AzK (red shape) provided in the culture medium and charges this residue onto the corresponding GYU anticodon-containing orthogonal pylT tRNA. Finally, the cell’s ribosomal translation machinery utilizes the resulting pools of AzK-charged tRNA (GYU) to specifically decode the AXC codon, allowing the production of site-specifically AzK-modified protein product (purple chain with red shape) in concert with the native translational machinery. **c.** Schematic showing an example AzK- IL-2 precursor molecule (purple chain with AzK incorporated). Reaction of the AzK-containing IL-2 proteins with DBCO-mPEG generates the site-specific and covalent attachment of the mPEG moiety to the AzK (one regiosomeric species shown). An array of different IL-2 variants with AzK incorporated into distinct sites was created and the scheme shown was employed to pegylate each variant.
immobilized on the surface of SPR sensor chips. Concentration series of rhIL-2 or THOR-707 were applied to these surfaces and receptor interactions were monitored as the change in response units (RU) as a function of time during association and dissociation phases. On IL-2Rα sensors, rhIL-2 showed a rapid association and slow dissociation kinetics, demonstrating high-affinity binding (Fig. 3b, upper left panel, Supplementary Table 2). In contrast, THOR-707 showed negligible interactions with the IL-2Rα surface even at the highest test concentration of 2 µM (Fig. 3b, upper right panel, Supplementary Table 2). Surfaces containing immobilized IL-2 Rβ showed similar association and dissociation responses with both rhIL-2 and THOR-707, with estimated dissociation constants (K_D) values of 0.285 and 1.96 µM, respectively (Supplementary Table 2). A THOR-707 compound containing a smaller (5 kDa) mPEG showed similarly negligible IL-2 Rα engagement, but 6-fold higher affinity to the IL-2 Rβ subunit (Supplementary Fig. 2 and Supplementary Table 2), suggesting the modest difference in K_D for the β subunit observed between compounds is likely due to nonspecific shielding effects of the large PEG as observed for other pegylated proteins16. These results suggest that THOR-707 is specifically defective in IL-2Rα interactions while largely retaining binding to IL-2Rβ.

Reprogrammed cell-specificity of THOR-707 for pSTAT5 signaling in primary human lymphocytes. To determine how the differential receptor specificity of THOR-707 affects activation of primary immune cell subpopulations, we profiled lymphocyte activation in human peripheral blood mononuclear cell (PBMC) samples using multi-color flow cytometry. Fresh Leukocyte Reduction System (LRS)-derived PBMC samples were treated with either rhIL-2 or THOR-707 in 5-fold dilution series starting with a top concentration of 30 µg/mL. After a 45 min incubation, samples were fixed and stained with antibodies to detect the phosphorylated form of the transcription factor STAT5 (pSTAT5), a marker of upstream engagement and Tumor cell lysis

Fig. 2 Overview of IL-2 pharmacology and therapeutic hypothesis of pegylated IL-2 with “not alpha” receptor specificity. a Schematic depicting IL-2 receptor biology, highlighting the desired and undesired effects of IL-2 therapy. To stimulate anti-tumor responses, high IL-2 (purple chain) concentrations are required to agonize the IL-2Rβγ complex (cyan and green chains) on CD8+ T and NK cells, driving activation and proliferation needed for tumor destruction. However, immune cell types with undesired biological activities also express the IL-2Rα chain, allowing their response to lower IL-2 concentrations. This results in Treg-mediated suppression of effector T cell populations, or stimulation of ILC-2 cells (not shown), which release IL-5 to drive VLS indirectly via eosinophil activation9. Therefore, the high rhIL-2 concentrations required to drive efficacy also result in Treg activation and toxicity in an IL-2Rα dependent manner. Blocking engagement of IL-2Rα may provide an improved therapy with reduced undesired target activation. b Concept of a site-specific PEG-modified “not alpha” IL-2, in which PEG attachment at the IL-2Rα interface blocks IL-2Rα engagement. The resulting compound allows normal IL-2Rβγ signaling and extends half-life via increased molecular size (not shown). Schematic of IL-2 (left) and THOR-707 (right) binding to the IL-2 receptor complex. Human IL-2 (purple chain) forms a heterotrimeric complex with the IL-2 receptor βγ (cyan), γ (green) and α (blue) subunits. Site-specific PEG modification (orange polymer) of THOR-707 at the IL-2 Rα receptor interface allows targeted reduction of the IL-2 Rα engagement without specific reduction in the engagement of the IL-2 Rβγ complex.
activation of IL-2 receptor signaling complexes and a panel of surface markers to follow pSTAT5 formation in specific T and NK cell subpopulations.

In NK and effector T cell (CD3+ CD8+) populations, THOR-707 retained potency relative to rhIL-2, with EC\textsubscript{50} values for pSTAT5 induction within 5–10-fold of the native cytokine (Fig. 3c and Supplementary Table 2). In contrast, the EC\textsubscript{50} value for THOR-707-induced pSTAT5 signaling in the Treg subpopulation (CD3+ CD4+ IL-2R\textalpha+ CD127−) was reduced by >2000-fold compared to rhIL-2 (Fig. 3c and Supplementary Table 3). This substantial decrease in potency for THOR-707 specifically in the Treg population indicates that pegylation of IL-2 at position 65 allows potent agonism of IL-2 receptors yet eliminates the strong bias of IL-2 for Treg stimulation relative to effector T cells. Indeed, the Teff/Treg EC\textsubscript{50} ratio for rhIL-2 was 216 (7.5 vs 0.035 ng/mL) compared to 1.3 (92.5 vs 73 ng/mL) for THOR-707. These results demonstrate that THOR-707 is a potent IL-2R\betaγ agonist with a greatly reduced bias for stimulating IL-2R\alpha-expressing Treg cells.

Reduction in THOR-707 engagement of IL-2 R\alpha is mediated by AzK substitution at P65 and pegylation. The proline residue at position 65 in human IL-2 appears to impart a significant bend.
in helix H3, a region that mediates substantial interactions with IL-2 Ra. As the sequence of THOR-707 contains a substitution of this proline to a lysine-like residue, we reasoned that this modification might result in a distinct helical conformation that mis-aligns residues critical for IL-2 Ra engagement. To elucidate the tertiary structure of the THOR-707 protein component, the crystal structure of the human IL-2 variant P65K was solved at 1.8 Å resolution (Supplementary Fig. 3B and Supplementary Tables 4, 5). The lysine residue incorporated at position 65 was selected to mimic the effect of the AzK substitution of this position on protein structure, as lysine constitutes the majority of the backbone of the AzK residue without the excessive hydrophobicity of the un-conjugated azide (Supplementary Fig. 3A). Surprisingly, the structure of the IL-2 P65K was remarkably similar to that of rhIL-2. Structural alignments show that the lysine substitution for proline at position 65 did not result in large-scale changes to the IL-2 tertiary structure, including the conformation of helix H3 (Supplementary Figs. 3B and 4A). Consistent with the above biochemical and ex vivo data, an inspection of the P65K region in the structure shows that this modification occupies a region of the IL-2/IL-2 Ra interface that mediates productive interactions (Supplementary Fig. 4B, C). Together, these results suggest that steric effects of the AzK and potentially the PEG modifications largely drive the reduction in IL-2 Ra potency of THOR-707.

To determine the relative contributions of proline 65 substitution with AzK and pegylation of this residue to the reduction in IL-2 Ra engagement and IL-2 Ra potency, we generated variants with structural elements of the THOR-707 modifications, including replacement of proline 65 with AzK (without PEG attachment), pegylation with a 5 kDa mPEG and the full THOR-707 compound with 30 kDa mPEG modification. The cell-specific potency for each compound was measured using the human PBMC assay for pSTAT5 activation using flow cytometry described above. At CD8+ T cells, the potency for pSTAT5 induction by rhIL-2 was ~175-fold higher than P65 AzK (31.1 vs 5446 pg/mL, respectively, Supplementary Fig. 5) demonstrating that AzK modification itself can contribute substantially to reduction in IL-2Ra engagement. Furthermore, the pegylated THOR-707 compounds showed a modest reduction in potency at Treg cells similar in magnitude to the potency reductions at CD8+ T cells, (5 vs 11.5-fold, respectively for 5 and 30 kDa mPEG variants of P65, Supplementary Fig. 5). The similar stepwise and minor reductions in potency of PEG size variants in both CD8+ T cells and Tregs suggest that PEG polymers are not specifically required to prevent IL-2 Ra engagement, but may impact potency in THOR-707 via non-specific envelopment as observed with other pegylated cytokines. Together, these results suggest that steric effects mediated largely by the substitution of proline 65 with AzK result in the reduction in IL-2 Ra engagement by THOR-707.

THOR-707 demonstrates increased half-life and improved plasma pharmacokinetics in mice. Due to the large increase in molecular weight, the attachment of a large 30 kDa mPEG polymer to THOR-707 was expected to affect the exposure of the molecule in vivo. To evaluate the pharmacokinetic properties and distribution of THOR-707 compared to rhIL-2, single intravenous doses were administered to naive C57BL/6 mice. Following administration, the THOR-707 exposure was 200 times higher than aldesleukin (AUC0–∞, Supplementary Fig. 6, Supplementary Table 6). In addition, THOR-707 demonstrated a 23-fold extended terminal t1/2 compared to aldesleukin (13.3 vs. 0.57 h, respectively, Supplementary Table 6). The THOR-707 volume of distribution at steady state (Vss; 82.4 mL/kg) was about 4.7-fold reduced relative to aldesleukin and similar to the blood volume for mice (85 mL/kg), suggesting that THOR-707 is mostly distributed within the systemic circulation as is typical of pegylated proteins.

THOR-707 drives sustained pSTAT5 signaling, Ki-67 expression and expansion of CD8+ T and NK cells in naive mice. The increased exposure observed for THOR-707 relative to rhIL-2 in mice suggested that THOR-707 may drive sustained signaling and result in an increased expansion of target CD8+ T and NK cells. To measure and compare the pharmacodynamics of these compounds, peripheral blood samples collected from naive mice dosed with THOR-707 or rhIL-2 were analyzed using multi-parametric flow cytometry measuring cell-specific signaling and proliferation.
THOR-707 dosing induced persistent pSTAT5 signaling in peripheral blood cell populations up to ~72 h for CD8+ T cells and 96 h for NK cells, while pSTAT5 in these cell types returned to baseline after only 2 h in mice dosed with a molar equivalent of aldesleukin (Fig. 4 and Supplementary Fig. 7). Due to the high-affinity binding of aldesleukin to IL-2Ra, pSTAT5 induction in Treg cells lasted for about 24 h before returning to the baseline (Supplementary Fig. 8). In contrast, the increased exposure of THOR-707 extended pSTAT5 signaling in Tregs, but was similar in duration to that of CD8+ T and NK cells, consistent with normal IL-2 Rβγ signaling without IL-2 Rα binding.

In addition to pSTAT5 induction, a single dose of THOR-707 induced the rapid disappearance of CD8+ T and NK cells from the peripheral blood within the first 10 h post-administration, suggesting activation and extravasation of these cells as previously demonstrated for rhIL-2 (Foreau et al.19). Beginning 12–24 h post-dose, THOR-707 induced expression of Ki-67, a nuclear protein marker for cell proliferation, in all three cell populations (CD8+ T, NK and Treg cells) to a similar degree across all dose levels, while induction of Ki-67 with aldesleukin treatment was not observed (Supplementary Fig. 9). THOR-707 resulted in proliferative responses of NK and CD8+ T cells (Fig. 4b, c, respectively) and phenotypic analysis of the resulting CD8+ T cell population using flow cytometry revealed substantial expansion of CD44+ memory cells within this population (Supplementary Fig. 10). The proliferative response in CD8+ T and NK cells was not observed in the rhIL-2 treatment group. Finally, THOR-707 dosing stimulated only low and transient levels of Treg cell expansion (Fig. 4d). These results suggest that the increased exposure of THOR-707 drives extended pSTAT5 signaling, extravasation and proliferation of peripheral CD8+ T and NK cells, without driving a significant expansion of peripheral Treg cells in naive mice.

THOR-707 elicits CD8+ T and NK cell proliferation with reduced IL-5 release, a biomarker for VLS, relative to high-dose IL-2. The pronounced pharmacodynamic response induced by THOR-707 administration to mice demonstrates that this compound is an efficient inducer of CD8+ T and NK cell proliferation. Previous studies demonstrated that CD25 engagement by IL-2 is required to induce vascular leak syndrome5,9, a severe adverse event observed with high-dose IL-2 therapy. To study whether THOR-707, a "not alpha" IL-2 may have the potential for an improved safety profile, naive mice were administered THOR-707 or aldesleukin and plasma samples were collected at intervals post-dosing to monitor CD8+ T and NK cell proliferation via flow cytometry, as well as plasma IL-5 cytokine levels.

Fig. 4 A single dose of THOR-707 drives sustained pSTAT5 signaling, extravasation and proliferation of CD8+ T and NK cells without significant Treg expansion in naive mice. A single intravenous bolus dose of 0.3 mg/kg rhIL-2 or THOR-707 was administrated to naive mice and blood was drawn via cardiac puncture at the indicated time points. Immune cell identification and signaling were assessed by flow cytometry, each data point represents an average of 3–4 replicates at each time point ± standard deviation (SD). a Percentage peripheral blood CD8+ T cells that are pSTAT5 positive. b Percentage of peripheral CD3+ cells that are CD8 positive. c Percentage of singlets (peripheral blood cells sampled) that are NK cells. d Percentage of CD3+ T cells that are CD44+ Treg cells (n = 4 animals). Source data are provided as a Source Data file.
levels, a biomarker for severe rhIL-2 toxicity, specifically VLS\(^+\). Under these conditions, a single dose of THOR-707 induced significant CD8\(^+\) T and NK cell proliferation that exceeded levels induced by rhIL-2 (Aldesleukin, Supplementary Fig. 11A, B). However, plasma IL-5 levels in response to THOR-707 were substantially lower compared to those induced by rhIL-2 ( Supplementary Fig. 11C, D and Supplementary Table 7). These results confirm that, compared to rhIL-2, THOR-707 drives stronger activation and expansion of peripheral effector T and NK cell populations while inducing significantly lower levels of IL-5, which promotes VLS\(^+\).

**THOR-707 shows enhanced accumulation and retention in tumor tissue relative to plasma and other tissues.** The pharmacokinetic properties and distribution of THOR-707 in tumor tissue versus plasma were analyzed in C57BL/6 mice bearing subcutaneous B16-F10 tumors. Following a single intravenous dose, THOR-707 exposure in both the plasma as well as the tumor increased in an approximately dose-proportional manner (Supplementary Table 8, Supplementary Fig. 12). The t\(_{1/2}\) in tumor tissue was nearly twice that in plasma (24.6 vs. 12.6 h for the 3 mg/kg dose group), indicating that THOR-707 distributes into the tumor and is retained intratumorally for a longer duration relative to the blood compartment (Supplementary Fig. 12).

To assess the specificity of THOR-707 accumulation in tumor relative to other tissues, THOR-707 levels were also analyzed in the splenic tissue from the THOR-707 dosed animals. After dosing, spleen exposure levels increased in an approximately dose-proportional manner and the apparent t\(_{1/2}\) of THOR-707 was shorter in the spleen compared to plasma or tumor (10.8 and 10.2 h in the 1 and 3 mg/kg dose groups, respectively, Supplementary Fig. 12 and Supplementary Table 8). These data demonstrate that THOR-707 distribution and retention in tumors is enhanced relative to organ tissue, consistent with observations with other pegylated proteins\(^{80}\).

**THOR-707 induces memory CD8\(^+\) T cell proliferation and lymphocyte expansion in mouse B16-F10 tumors and controls tumor growth.** The preferential accumulation of THOR-707 in tumor tissue suggested that this compound may drive additional pharmacodynamics within tumors. Peripheral blood, tumor tissue and splenic tissue was collected at day 5 post-dosing and tissue-resident lymphocyte populations were isolated and characterized using flow cytometry. Analysis of tumor samples revealed significant expansion of both CD8\(^+\) T and NK cells within the tumors of THOR-707-treated mice relative to vehicle-treated mice (Fig. 5c). In contrast, the Treg cell population did not expand within the tumor relative to the vehicle control (Fig. 5c).

To determine whether THOR-707 also drives effector cell proliferation in, or trafficking to, lymphoid tissues, the effect of THOR-707 dosing on lymphoid cells in the spleen was characterized. Spleens were harvested on days 5 and 7 from B16-F10 tumor-bearing mice following a single 3 mg/kg dose of THOR-707. Similar to the tumor compartment, in the spleen, a marked expansion of CD8\(^+\) T and NK cells was observed in THOR-707-treated animals, while no significant change in CD4\(^+\) Treg population was observed (Fig. 5d), resulting in a progressive increase in the splenic CD8\(^+\) T/Treg ratio at days 5 and 7 post-dose (Supplementary Fig. 13). Together, these results suggest that THOR-707 drives the proliferation of NK and CD8\(^+\) T cells in peripheral blood, tumor and spleen tissue without induction of suppressive CD4\(^+\) Treg subpopulations.

In addition to inducing a significant expansion of CD8\(^+\) T cells in tumors, THOR-707 administration resulted in a dose-dependent inhibition of B16-F10 tumor growth (Fig. 6a). The tumor volumes from each dose group showed reduced kinetics of outgrowth with increasing dose, and scatter plots of individual tumor volumes at day 14 showed statistically significant anti-tumor activity, with mean tumor volume reductions of 29% (p = 0.043) and 40% (p < 0.001), compared to vehicle control at 3 and 6 mg/kg dose groups, respectively (calculated using one-way ANOVA, Fig. 6b). These results demonstrate that THOR-707 treatment as a monotherapy demonstrates the capacity to reduce B16-F10 tumor progression in mice.

**Discussion**

To overcome the limitations of aldesleukin therapy, including expansion of Treg cells and induction of vascular leak syndrome, we applied a synthetic biology platform to engineer a potentially safer and more efficacious version of rhIL-2. Using an engineered organism with a semi-synthetic, six-letter DNA code, we generated a library of genetically encoded rhIL-2 variants with a site-specific azide-containing residue, then specifically and covalently pegylated these variants using click chemistry. This approach enabled the identification of pegylated IL-2 variants that were difficult or impossible to produce using standard methodologies such as site-directed mutagens or lysis-mediated chemical coupling. Another method to incorporate non-natural amino acids into proteins includes stop codon suppression, which reappropriates a genetically redundant stop codon (typically amber UAG) to direct the site-specific incorporation of a non-natural amino acid into a polypeptide via an orthogonal tRNA/trna synthetase system. This method involves competition between release factor binding and tRNA-mediated decoding and results in abundantly expressed product truncations or requires extensive genome recoding and strain optimization to mitigate\(^{21}\). In contrast, the semi-synthetic organism technology presented here allows site-specific incorporation of a non-natural amino acid without competition with dedicated translation factors and may enable more streamlined processing due to higher yields and reduced truncated product formation. This technology may therefore represent a general tool for the engineering of enhanced biologics that are compatible with microbial production.

Applying the semi-synthetic organism technology to drug discovery, we generated and screened an array of peg-modified variants of IL-2 and discovered THOR-707, a pegylated IL-2 with differentiated pharmacological properties. Our in vitro and ex vivo studies demonstrated that THOR-707 is a potent stimulator of CD8\(^+\) T and NK cells, which expresses the IL-2 R\(βγ\) complex. Compared to aldesleukin, THOR-707 showed a
specif
cially reduced potency for stimulation of suppressive Treg
cells, demonstrating that the pharmacology of THOR-707 is
reprogrammed toward stimulation of effector populations
required for a potent anti-tumor response. In mice, THOR-707
demonstrated an extended half-life and reduced volume of dis-

circulation compared to rhIL-2 (Supple-

Fig. 5 THOR-707 induced the expansion of peripheral, intratumoral and splenic CD8$^+$ T and NK cells in B16-F10 tumor-bearing C57BL/6 mice. a
Percentage of CD8$^+$ memory T cells within the CD3$^+$ T cell population up to 10 days post-dose of a single 1 or 3 mg/kg intravenous bolus dose of THOR-707 to tumor-bearing mice. Bars represent an average from 4 replicates at each time point (except n = 7 for 3 mg/kg at days 3, 5, 7), shown as individual points. *p < 0.05, **p < 0.01, ***p < 0.001 using unpaired, non-parametric t-test. b Ratio of CD8$^+$ T cell vs. CD4$^+$ Treg cells in the peripheral blood following administration of a single 1 or 3 mg/kg intravenous bolus dose of THOR-707 to B16-F10 tumor-bearing mice. Bars represent an average from 4 replicates at each time point (except n = 7 for 3 mg/kg at days 3, 5, 7), shown as individual points. *p < 0.05, **p < 0.01, ***p < 0.001 using unpaired, non-parametric t-test. c Percentage of NK cells in CD3$^+$ T, CD8$^+$ T and Treg cells in the tumor CD3$^+$ T cell population following treatment with a single 1 or 3 mg/kg intravenous bolus dose of THOR-707. Tumor samples were analyzed for immune cell populations 5 days after treatment by FACS (data represented for day 5). Bars represent an average from 4 replicates at each time point (except n = 7 for 3 mg/kg at days 3, 5, 7), shown as individual points. *p < 0.05, **p < 0.01, ***p < 0.001 using unpaired, non-parametric t-test. d Percentage of NK cells in CD3$^-$ cells, CD8$^+$ T and Treg cells in the spleen CD3$^+$ T cell population following treatment with a single 3 mg/kg intravenous bolus dose of THOR-707. Spleen samples were analyzed for immune cell populations 5 days after treatment by FACS. Bars represent an average of 4 replicates at each time point shown. *p < 0.05, **p < 0.01, ***p < 0.001 using unpaired non-parametric t-test. Source data are provided as a Source Data file.

specifically reduced potency for stimulation of suppressive Treg
cells, demonstrating that the pharmacology of THOR-707 is
reprogrammed toward stimulation of effector populations
required for a potent anti-tumor response. In mice, THOR-707
demonstrated an extended half-life and reduced volume of dis-

Inflamed vascular tissue within the tumor and we speculate that
tumor retention may increase the local efficacy of the compound
for effector cell expansion.

In additional to improved exposure and tissue distribution,
THOR-707 administration elicited robust, cell-specific activation
and proliferation of effector lymphocyte populations in mice. A
single dose of THOR-707 increased memory CD8$^+$ T and NK cell
proliferation in the peripheral blood (Figs. 4 and 5). Despite
pSTAT5 and Ki-67 induction in Tregs, THOR-707 administration
did not induce Treg expansion (Figs. 4 and 5), suggesting that IL-
2Ra-mediated signaling and/or additional stimulatory signals are
required for either Treg proliferation or survival.

Previous studies demonstrated a requirement for IL-2Ra
engagement for high-dose IL-2 induction of VLS, a severe and
under clinical investigation. Approaches to reduce IL-2R pharmacology have been reported, several of which are currently intervals post-dose initiation of treatment, indicated by black arrows, and percentages indicate the percent reduction in mean tumor volume observed at day 14. Tumor volumes (mm^3) measured at day 14 post-dose initiation are plotted for different dose groups. Each point indicates an individual tumor, mean tumor volume (horizontal line with error bars representing ± SEM) is shown. n = 15 animals. **p = 0.0043, ***p < 0.0001 using one-way ANOVA. Source data are provided as a Source Data file.

Often a fatal adverse event observed with IL-2 therapy. As THOR-707 is a “not alpha” IL-2, we compared the capacity of THOR-707 and rhIL-2 for induction of plasma IL-5, a key mediator of eosinophil activation, shown by Bluestone and co-workers to be a strong biomarker for VLS. Under conditions that drive improved CD8^+ T and NK cell proliferation, THOR-707 induced significantly lower plasma IL-5 levels relative to rhIL-2 (Supplementary Fig. 1A–D and Supplementary Table 7). These results suggest that THOR-707 drives enhanced pharmacodynamic response in CD8^+ T and NK cells with reduced potential for severe adverse events such as VLS compared to rhIL-2.

In B16-F10 tumor-bearing animals, THOR-707 administration drove the marked expansion of CD8^+ T and NK cells within tumor and spleen tissues without stimulation of Treg expansion (Fig. 5 and Supplementary Figs. 9, 14 and 15). Tumor-bearing mice administered THOR-707 showed a dose-dependent and significantly lower tumor size after only two doses of the compound (Fig. 6). Additional efficacy studies employing alternative tumor models may provide further insight into the anti-tumor activities of THOR-707 alone and in combination with immune-modulating compounds such as checkpoint inhibitors.

In addition to THOR-707, a variety of IL-2-based drugs that utilize alternative strategies for half-life extension and “not alpha” pharmacology have been reported, several of which are currently under clinical investigation. Approaches to reduce IL-2Ra engagement include IL-2 muteins containing amino acid substitutions to block IL-2Ra binding, non-specific and hydrolysable pegylation, IL-2Ra fusions and antibody complexes or fusions. While clinical proof-of-concept for additional “not alpha” IL-2 molecules in humans is growing, fusion molecules and muteins by definition create neo-epitopes that may generate an anti-drug immune response and potentially even antibodies against a patient’s endogenous protein. In contrast, THOR-707 has been engineered to reduce the potential for immunogenic response: the PEG attachment is positioned within a region of the IL-2 molecule that has a weak propensity to provide the P1 anchors required for class II MHC presentation. The large mPEG attached to this position is covalent, highly stable and irreversible and expected to prevent processing at multiple steps in the MHC-II presentation pathway. Therefore, unlike alternative IL-2 compounds in development, the chemically modified region of THOR-707 may block immune surveillance pathways that could lead to anti-drug antibody formation.

Overall, this work represents a seminal step in synthetic biology- the application of a semi-synthetic genetic system for the engineering, discovery and manufacturing of an improved, chemically modified protein pharmaceutical candidate. Looking ahead, the myriad new codons afforded by the X-Y genetic code will likely enable multiple distinct chemical functionalities to be designed into proteins for increased, combinatorial complexity to overcome multiple distinct limitations of native protein drugs. What was historically the exclusive domain of small molecule and peptide synthesis, the capacity to apply medicinal chemistry-like approaches to engineer full-length recombinant proteins with unique functions will enable a new frontier in biological medicines.

Methods

Ethical approval statement. The studies performed by the authors reported herein that make use of human blood samples were collected from anonymous healthy donors and were approved by local institutional review boards. All subjects provided informed consent. The studies were performed following the guidelines of the World Medical Association’s Declaration of Helsinki. All procedures performed in studies involving animals reported here were conducted following guidelines for animal welfare which comply with the U.S. Department of Agriculture’s Animal Welfare Act (9 CFR Parts 1, 2 and 3) as applicable.

Molecular biology reagents and assay materials. All primers for PCR amplification were purchased from Integrated DNA Technologies (Coralville IA). All unnatural oligonucleotides were synthesized by Biosearch Technologies (Petaluma, California, USA) with purification by reverse phase cartridge. Phosphoramidites of dTPT3 and dTPT3 were synthesized by WuXi AppTec (Tanjin China). The dNAM, dTPT3, NaM and TPT3 nucleosides were synthesized by WuXi AppTec and then triphosphorylated by MyChem LLC (San Diego CA). Analytical data for custom nucleotides are summarized in Supplementary Table 9 below. Plasmid clean-up for cloning plasmids was performed using QIAprep commercial kits (QIAGEN). All cloning enzymes were purchased from New England Biolabs (Ipswich, MA), gBlock® gene fragments and natural oligonucleotides (with standard purification
and desalting) were purchased from IDT (Corvallis, OR). Sequencing was performed by Genewiz (San Diego, California, USA). Plasmids were isolated using commercial methods (Qiagen, Qiaprep Spin Miniprep Kit (Qiagen Zymo Research), PCR reactions for amplification of DNA used TempAssure PCR 8-Tube Strips (USA Scientific, Cat. No. 1402-2380) with a Roche Life Science LightCycler 96 Q-PCR thermocycler. DNA Clean and Concentrator kits from Zymo Research were used for purification of all Golden Gate Assembly reactions and Golden Gate vector and insert fragments. Both Golden Gate DNA Polymerase and Gibson Assembly protocols were performed on a MJ Research PCT-200 Thermal Cycler. DNA quantitation was carried out using Qubit DNA HS Assay Kits (Molecular Probes, Cat. No. Q32834). A list of primers used in these studies is included in Supplementary Table 10 below.

**Growth media and antibiotics.** All liquid bacterial cultures were grown in 2xYT (ThermoFisher Scientific, Cat. No. BP7936) with the addition of additional chemicals and antibiotics as indicated, shaking at 250 rpm with a 1° throw. Liquid bacterial cultures were grown in 2xYT supplemented with potassium phosphate (50 mM, pH 7) by adding 30.75 mL 1 M Potassium Phosphate Dibasic Solution (Sigma, Cat. No. P8584-4L) and 19.25 mL 1 M Potassium Phosphate Monobasic Solution (Sigma, Cat. No. P8709-4L) (hereafter referred to as 2xYTP). Overnight liquid cultures were grown in 50 mL Bio-Reaction Tubes (CellTreat Scientific Products, Cat. No. 229475) using 2xYTP media. Small scale protein expression experiments were performed using overnight cultures grown in 17×100 mm test tubes (Fisherbrand, Cat. No. 14-956-1) to seed 25 mL media in 125 mL baffled culture flasks (Fisherbrand, Cat. No. 134115). E. coli cultures were incubated at 37 °C using a Kuhner ISF-1-W Incubator Shaker using a 1° throw at 250 rpm. The optical densities of the bacterial cultures were measured using 1.5 mL semi-micro cuvettes (Fisherbrand, Cat. No. 14955127) and an Implen P30 Nanophotometer set to 600 nm and blanked with sterile growth media. Antibiotics used consisted of ampicillin (100 µg/mL), chloramphenicol (5 µg/mL) and zeocin (50 µg/mL), all purchased commercially. Cultures were supplemented using N2- (2-azidoethoxy)-carbonyl-L-lysine hydrochloride (hereinafter referred to as AzK) purchased from Synchem (Buffalo Grove, IL) and prepared to a 1 M stock solution in nuclease-free water.

**Construction of PylRS-expressing plasmid.** The plasmid pS321 (pGEX-MbPyRS) was constructed by gene synthesis of a fragment corresponding to the sequence of the *M. barteri* pyrR (pyr) and *M. barteri* pyrM (pyrM) genes flanked by overnight cultures containing 5× (94 °C 0:30 | 56 °C 0:05 | 68 °C 4:00), then 10× (94 °C 0:30 | 62 °C 0:05 | 68 °C 1:30) cycles: | 5 × (94 °C 0:30 | 65 °C 0:05 | 68 °C 4:00), then | 10 x (94 °C 0:30 | 62 °C 0:05 | 68 °C 4:00). Inserts were amplified with the following thermocycling conditions (times denoted in minutes): 15 min after pre-induction, cultures were induced with 1 mM IPTG and incubated for an additional 15 min. The cells were chilled on ice and an equal volume of 50% glycerol was added and mixed. The mixture was aliquoted, frozen in liquid nitrogen and stored at −80 °C.

**Expression strain generation.** The *E. coli* BL21(DE3) variant YZ35, which constitutively expresses a truncated version of the PNT2 T2 nucleotide transporter from *P. tricornutum*, was obtained from the Ronesberg lab at TSRi (San Diego). This strain was then transformed with a *C. albicans* chemical transformation plasmid pSyn321 (described above), plated on 2xYT agar containing 100 µg/mL ampicillin and 5 µg/mL chloramphenicol and incubated overnight at 37 °C. A single isolated colony was inoculated into a 2xYT medium containing 100 µg/mL ampicillin and 5 µg/mL chloramphenicol and grown overnight at 37 °C at 250 rpm shaking. The resulting culture, termed SYTX strain 37, was mixed 1:1 with 50% glycerol, frozen in liquid nitrogen and stored at −80 °C.

To generate the AzK-substituted IL-2 expression strains, an overnight culture of the parent strain STTX169 was inoculated into 10 mL 2xYT media containing 5 µg/mL chloramphenicol, 5 µg/mL tetracycline and 50 mM potassium phosphate. The next day the culture was diluted back into an OD of 0.0025 using 50 mL fresh media, and the culture was grown until an OD of 0.4. The cells were then chilled by swirling on ice for 5 min and centrifuged at 3000×g for 10 min at 4 °C. The resulting cell pellet was washed twice with an equal volume of pre-chilled sterile deionized water and resuspended in 2×YTP. After centrifugation and resuspension, the cells were spun down a final time to remove excess water and resuspended in 300 µL of fresh pre-chilled sterile deionized water, in which 50 µL of the cells were used for electroporation with the following conditions: Voltage: 2.5 kV, Capacitor: 25 µF. Resistor: 200 Ω using a BioRad Gene Pulser II Electroporation System and a 2 mm hole electrode. The resulting electroporated cells were then incubated at 37 °C with 5 µg/mL chloramphenicol was added to the electroporated cells in which 44 µL of cells were added to 180 µL of 2xYTP + 5 µg/mL chloramphenicol with 187.5 µM dNaMTP and 47 µM dTP3T3P to rescue at a final concentration of 150 µM dNaMTP and 37.5 µM dTP3T3P. The cells were rescued at 37 °C shaking at 250 rpm for an hour and 100 µL of the rescued electroporated cells was inoculated into 3 mL of 2xYTP containing 5 µg/mL ampicillin, 50 µg/mL zeocin, 150 µM dNaMTP and 37.5 µM dTP3T3P and grown overnight. The next day the culture was expanded to 50 mL in the media and the culture was monitored until reaching an OD of 1.0 at which the cells were chilled on ice and an equal volume of 50% glycerol was added and mixed. The mixture was aliquoted, frozen in liquid nitrogen and stored at −80 °C.

**Preparation of pegylated and un-pegylated IL-2 variants.** Expression of IL-2 variants with AzK substitutions was performed in 2xYT medium (Thermo Fisher Scientific, Cat. No. BP7936) supplemented with 50 mM potassium phosphate, 100 µg/mL ampicillin, 5 µg/mL chloramphenicol, 50 µg/mL Zeocin, 150 µM dNaMTP and 37.5 µM dTP3T3P. Expression seeds were incubated overnight at 37 °C, diluted prior to reaching OD600nm of ~0.8, cultures were pre-induced with 250 µM NaNTP, 25 µM TTP3T3P and 10 mM AzK-HCl prepared in deionized water (Synchem, Buffalo Grove IL, product #36462). Approximately 15 min after pre-induction, cultures were induced with 1 mM IPTG and incubated for an additional 20 min at 37 °C. The cells were then chilled on ice and an equal volume of 50% glycerol was added and mixed. The mixture was aliquoted, frozen in liquid nitrogen and stored at −80 °C.

Inclusion bodies were generated by the addition of 50 mL lysis buffer (1x PBS, Thermo Fisher Scientific, Cat. No. BP2940-4) containing protease inhibitors (Thermo Fisher Scientific, Cat. No. A52965) and lysozyme (ThermoFisher Scientific, Cat. No. 89833). Cultures were incubated on ice for 30 min. To pre-equilibrate, Ni-NTA resin (ThermoFisher Scientific, Cat. No. 269960) was added to the lysis buffer. Resuspended. Resuspended lysates were lysed by passing twice through a microfluidizer (Dyhydrodynamics, model M110L). Lysed samples were centrifuged at 30,000 × g for 25 min at 4 °C before decanting and discarding the supernatant. Inclusion body pellets were solubilized by addition of 25 mL 6 M Guanidine-HCl in 100 mM Tris-HCl pH 8, 20 mM imidazole per liter, pipetting until sample homogeneity before agitation for 15 min on a rotator. Samples were again centrifuged at 30,000 × g for 20 min at 4 °C and pellets were discarded.

To pre-equilibrate, Ni-NTA resin (Thermofisher Scientific, Cat. No. 25216) was pre-washed with solubilization/wash buffer (6 M Guanidine-HCl, 100 mM Tris-HCl pH 8, 20 mM Na2EDTA) and loaded onto the column. The elution buffer used was 5% glycerol solubilized sample in conical tubes and incubated for 1 h at 4 °C on a rotator. The resin was collected by centrifugation for 2 min at 250 g and the flow-through was removed. The resin was washed with 10–15CV of solubilization/wash buffer, transferred to a collection column and washed for an additional 10 column volumes of solubilization/wash buffer. The column was eluted using 3 CV of elution buffer (1x solubilization/wash buffer containing 500 mM imidazole). Eluates were dialyzed overnight in 12 L of 20 mM Tris-HCl pH 8/150 mM NaCl, then moved to 12 L of 20 mM Tris-HCl pH 8/50 mM NaCl for an additional 4 h. The resulting dialysate was centrifuged at 30,000 x 20 min at 4 °C and supernatant was collected.

Samples were transferred to 50 mL conical tubes and 0.25 mL enterokinase (NEB cat# P8070L) was added per 5 µg of protein. Samples were mixed by inversion and incubated overnight at room temperature for enzymatic digestion. The peylation reaction was initiated by the addition of 5 mM DBCO-mPEG (30 kDa Click Chemistry Tools, cat# A121, 10 kDa cat # A119, or 5 kDa cat # A118) stock to a final concentration of 50 µM and incubated overnight at 4 °C. Samples were...
concentrated using an Amicon-15 before loading onto HiLoad 16/600 Superdex 200 pg size-exclusion chromatography column (GE Healthcare) using an AKTA Pure system (GE Healthcare). The eluent (PBS containing 1% BSA) was filtered using a 0.2 µm filter and run at 1 ml/min. A total of 20 fractions of interest were analyzed by SDS-PAGE on a BioRad AnyDx TGX Pre-cast gel followed by western blot using rabbit anti-IL-2 oligoclonal antibody (ThermoScientific, Cat. No.710146). Peak fractions were pooled and adjusted to a final concentration of 0.5% acetonitrile 0.043% Trifluoroacetic acid. Samples were loaded onto a 3 ml RPC column (GE Healthcare) eluted with 0.1% Trifluoroacetic acid and eluted using a gradient of buffer B (90% Acetonitrile/0.028% Trifluoroacetic acid). Fractions corresponding to the peak of interest were analyzed by SDS-PAGE and western blot as above, pooled and mixed 1:1 with dOxO Protein A. Using a Labconco Frontier, the lyophilized samples were then resuspended in 50% acetonitrile 0.1% TFA and quantitated using a BSA standard curve with the BCA method to determine final concentration prior to final lyophilization as above. Samples were stored lyophilized at −80 °C until use.

**Discoverys PathHunter screening for pegylated IL-2 variants with “not alpha” pharmacology.** Primary human PBMCs were recovered from heparinized blood samples from healthy donors. The LRS chambers were drained into a 50 mL conical tube and the volume was adjusted to 20 mL using 1× PBS. Then 90 µL of the stock was aliquoted into the relevant wells of a 96-well-plate. The plate is warmed to 37 °C for 15 min prior to the addition of the compound.

**Compounds were diluted in PBS and the rh-IL-2 was diluted using PBS + 0.1% BSA to create 10x stocks. The 10x IL-2 stock concentration was µg/mL and the THOR-707 stocks were between 6 and 300 µg/mL depending on the experiment.**

**Cells were thawed at room temperature and TruStain FX® (Biorad 422302) was added with 15-fold dilution.** After 5 min at room temperature, cell surface antibodies were added. After 20 min at room temperature, cells were washed twice with PBS + 0.5% BSA and permeabilized by adding 10 volumes of Methanol (Fisher Chemical, Cat. #A412-4) to one volume of cells or Perm Buffer III (Becton Dickinson, Cat. #558050). The permeabilization was incubated for 10 ± min at 4 °C, washed with PBS, with PBS + 0.5% BSA and Fc block was added as above before the addition of the following post-permeabilization staining panel. The stained cells were incubated for 1 h at room temperature, washed twice with PBS with 0.5% BSA and prepared for flow cytometric analysis. The antibody details used in these procedures are provided in Supplementary Table 11 below.

**Flow cytometry assay for pSTAT5 induction in primary human PBMC.** The studies reported herein compiled with all relevant ethical regulations for animal testing and relevant local laws.

**Primary human PBMC potency studies using flow cytometry were performed under contract by PrimBio (Fremont CA). In the Discoverys PathHunter® Cytokine Receptor Assay, one cytokine receptor chain is tagged with a small fluorophore and the fcs files are annotated. The fcs files to a 1:1 interaction model to obtain binding parameters using Scrubber (v2.0c).**

**Surface plasmon resonance (SPR).** The SPR studies herein were performed under contract by Biosensor Tools LLC (Salt Lake City UT). The molecular mass of IL-2 samples was assumed to be 15.5 kDa. The 50-µg samples were dissolved in 50 µL water to make stock solutions of 64.5 µM. The Fc-tagged human IL-2 receptor subunits (extracellular domains) were purchased from Sigma Biochemical (I-h2-Ra-Fc Sino 10165-H02H, I-h2-Rb-Fc Sino 10166-H02H). Recombinant human IL-2 (i-h2) was purchased from Thermo Scientific (Cat. No. PHC0021) and prepared as a stock concentration of 64.5 µM.

**Using Biacore 2000 optical biosensor, the Fc-IL-2 receptor subunits were immobilized to Protein A-coated CM4 sensor chip to densities of ~160 fmoles/cm² and equilibrated with running buffer (10 mM HEPES, 150 mM NaCl, 0.005% Tween 20, 0.1 mg/mL BSA, pH 7.4).** Binding studies were performed at 25 °C. When BSA coated sensor surfaces were used, cell samples were used with 50 µg/mL phosphoric acid between binding cycles. The test articles were tested in duplicate, in two-fold dilution series starting at 2 µM. The responses from IL-2 B surfaces were fit to a 1:1 interaction model to obtain binding parameters using Scrubber (v2.0c).

**Flow cytometry assay for pSTAT5 induction in primary human PBMC.** The studies reported herein compiled with all relevant ethical regulations for animal testing and relevant local laws.

**Primary human PBMC potency studies using flow cytometry were performed under contract by PrimBio (Fremont CA) or internally. PrimBio purchased human blood samples through an IRB with Stanford University (Reg#: 5136 (protocol 13942) and 6208 (protocol 38735)). Internal blood samples collection from anonymous donors has been approved by the Institutional Review Board of The Scripps Research Institute (#177065). Leukocyte reduction systems (LRS) were purchased from Cell IDX (San Diego, CA). All subjects provided informed consent. The studies were performed following the guidelines of the World Medical Association’s Declaration of Helsinki.**

**Primary human lymphocyte populations from 3–6 (Peg size study (Supplementary Fig. 5) and pSTAT5 potency assay (Fig. 2), respectively) independent healthy donors were sourced and prepared from leucocyte reduction system (LRS) collected from anonymous healthy donors. Samples were treated in triplicate with either hIL-2 (Aldelesinukin) or THOR-707 in 3-fold dilution series starting at a concentration of 3000 µg/mL. A concentration of 3000 µg/mL was then fixed and stained with antibodies to detect pSTAT5, a marker of upstream engagement and activation of IL-2 receptor signaling complexes and a panel of antibodies that stain surface markers specific for lymphocyte populations of interest to follow pSTAT5 formation in specific T cell and natural killer (NK) cell subpopulations. The half-maximal effective concentration (EC50) levels for pSTAT5 signaling potency were measured in primary CD8⁺ T, NK and Treg cell subpopulations.**

**Lyophilized compound from the manufacturer was reconstituted according to the manufacturer’s recommendations. Briefly, the compound was resuspended in 0.1 M acetic acid to 2 mg/mL at room temperature and mixed by flicking.** Upon complete solubilization (by visual inspection for clarity), the compound was aliquoted into small aliquots, frozen in liquid nitrogen and stored at −80 °C. The hIL-2 (Gibco #PHC0233 or #PHC0272) or THOR-707 stocks were stored frozen in 0.1 M acetic acid prior to use in the assays. Stated concentrations throughout this report refer to the protein component of the pegylated compound to facilitate direct activity comparisons between pegylated and non-pegylated compounds.

**Human leukocyte reduction system (LRS) were received the same day as described above.** Healthy donors were preminary cell-based pharmacological screening was performed under contract at DiscoverX (Fremont CA). In the Discoverys PathHunter® Cytokine Receptor Assay, one cytokine receptor chain is tagged with a small fluorophore and the fcs files are annotated. The fcs files to a 1:1 interaction model to obtain binding parameters using Scrubber (v2.0c). The t8 using a 4-parameter logistic regression equation. The EC50 was calculated as the inflection point of the curve.
penicillin/streptomycin. All cells were maintained at 37 °C in a humidified incubator, with the atmosphere equilibrated at 10% CO2 and 90% air.

Subcutaneous xenograft. C57BL6 mice were housed at 72 ± 5 °F, ambient humidity and 12 h light:dark cycle. Animal welfare for this study complies with the U.S. Department of Agriculture’s Animal Welfare Act (9 CFR Parts 1, 2, and 3) as applicable. All experimental data management and reporting procedures were in strict accordance with applicable Crown Bioscience, Inc. Guidelines and Standard Operating Procedures. B16-F10 cells were washed in serum-free media, counted and resuspended in cold serum-free media at a concentration of 50,000 viable cells/0.1 mL. All cells were injected subcutaneously in the flank of the C57BL6 mouse. Tumor measurements were collected three times per week for the duration of the study using digital calipers. To calculate volume, a prolate ellipsoid model was used to estimate tumor volume (mm³) from two-dimensional tumor measurements:

\[
\text{Tumor volume (mm}^3\text{)} = \left(\frac{axb}{2}\right) + \frac{2}{3} \pi \frac{c^2}{2}
\]

Assuming unit density, volume was converted to weight (i.e., \(1 \text{ mm}^3 = 1 \text{ mg}\)). In the B16-F10 tumor PK/PD study, mice were randomized for treatment when the average tumor volume reaches 80–100 mm³. In the B16-F10 efficacy study, mice were randomized at 50 mm³ for the treatment. The starting of dosing day is designated as day 0.

Blood collection and processing for PK and PD immune cell profiling. After a single intravenous injection of mice with THOR-707, terminal blood samples were collected by cardiac puncture following CO2 euthanasia. For the study in naive mice, blood was collected at 13 time points (0.03, 0.17, 0.5, 1, 2, 4, 8, 12, 24, 48, 72, 96 and 120 h) post-dose, sacrificing 3 mice per time point. For the study in tumor-bearing mice, blood was collected at 9 time points (day 0 [2, 8, 12 h], 1, 2, 3, 5, 7 and 10 days) post-dose, sacrificing 4 mice per time point. 200 µL of plasma was collected for PK analysis.

For immune cell phenotyping, 400 µL of blood were treated with 20 volumes of pre-warmed Lyse/Fix Buffer (BD PhosFlow™, catalog #538049) and incubated for 10 min at 37 °C. Cells were spun for 8 min at 500 x g and washed twice with 5.0 mL of flow cytometry buffer (BD, catalog #561550). Lysed and fixed blood cells were first blocked with TruStain FcX (BioLegend, 101320) at room temperature for 5 min before the surface marker staining using the antibody cocktail shown below in the table. The cells were permeabilized with 4 °C pre-cooled methanol at room temperature for 10 min, followed by the intracellular staining with the antibody cocktail listed in the 2nd table. The events were acquired with Becton Dickinson Fortessa. The CD8+ T cells are then gated as the CD3+ CD4- CD8+ T population. The NK cells are identified as the CD3− NK1.1+ population. The Tregs were then gated from the CD4+ T cells as the CD25+ FoxP3+ population. The memory CD8+ T cells were identified as CD4+HIL CD8+ population. Data are represented as cell population as a percent of its parental or grandparental cell population. The antibody panel used to profile the immune cell phenotyping from whole blood is shown in Supplementary Table 12 below.

Tissue collection and processing. In the B16-F10 tumor PK/PD study, after a single intravenous bolus administration of THOR-707, the tumors and spleens were harvested at day 0 (2, 8, 12 h), 1, 2, 3, 5, 7 and 10, following CO2 euthanasia. The tumors were excised into two halves, one half was weighed and frozen down in liquid nitrogen for tumor PK analysis. Half of the tumors for flow cytometry analysis were processed right after collection. MACS mouse tumor dissociation kit (Miltenyi Biotec) was used to prepare tumor samples into single cells for flow cytometry analysis. Briefly, tumor samples were minced into small pieces, followed by mechanical and enzymatic digestion with Gentle MASC (Miltenyi Biotec). Mouse spleenocytes were dissociated by homogenizing spleens via straining using the plunger end of a syringe, then washed with 1× PBS, followed by red blood cell lysis with 1× red blood cell lysis buffer (Invitrogen, catalog #00-4333-57).

Tumor and spleen lysate preparation for pk analysis. Frozen tumor or spleen samples were homogenized with the lysis buffer (made by dissolving 1 tablet of protease inhibitor [SIGMA, catalog #4693159001] in 10 mL 1× PBS). Every 0.1 g tissue was mixed with 0.4 mL of that buffer. To each tissue collection tube, a 5 mm stainless steel bead was added (Qagen, catalog #699899) prior to homogenization with Tissue Lyser II (Qagen) at 20 Hz for 20 s. Following homogenization, the tissue tumor lysate was spun down and the supernatant was collected for THOR-707 PK analysis.

In vivo immune cell phenotyping in B16-F10 tumor PK/PD study. Lysed and fixed whole-blood samples from the B16-F10 tumor PK/PD study were analyzed with the same method as described above in the section “Blood collection and processing for PK and immune cell profiling”. The antibody panel used to profile the immune cell phenotyping for tumor and spleen samples in the B16-F10 tumor PK/PD study is shown in Supplementary Table 13 below.

IL-2 (P65K) protein production for crystallization. Crystallization studies were performed under contract by Proteros (Munich Germany). For crystallization studies, the His-IL-2 (P65K, C125S) protein variant was expressed in E. coli BL21(DE3) using 2×YT medium supplemented with 50 mM Potassium Phosphate and 50 µg/mL Zeco. The pellet from 3 L above culture was homogenized with Ultra Turrax in 150 mL 1× PBS pH 7.4 with DNaseI, 4 Roche Complete Tis and lysosome (1 mg/mL). After incubation on ice for 30 min, the sample was lysed using sonication 10 × 30 s. After centrifugation at 33,000×g (25 min, 4 °C) the resulting pellet was homogenized with Ultra Turrax and centrifuged again. The final pellet was solubilized in 75 mL 6 M Guanidine-HCl, 100 mM Tris-HCl pH 8 and 20 mM Imidazole.

The denatured His-IL-2 (P65K, C125S) protein was captured using 20 mL Ni-Sepharose using gravity flow, washed with 15 column volumes of 6 M Guanidine-HCl, 100 mM Tris-HCl pH 8, 20 mM imidazole before elution in 3 column volumes of 6 M Guanidine-HCl, 100 mM Tris-HCl pH 8, 500 mM imidazole. Eluate solution was dialyzed against 1 L 20 mM Tris/HCl pH 8, 150 mM NaCl overnight, centrifuged and dialyzed for another 4 h against 1 L 20 mM Tris/HCl pH 8, 50 mM NaCl.

The resulting protein was digested with enterokinase (100 U/mg). After 20 h digestion time, the resulting sample was concentrated to 1.5 mg/mL and purified on Superdex S-200 26/60 run at 2 mL/min in 20 mM Tris/HCl pH 8, 50 mM NaCl collecting 3 mL fractions. Fractions containing the peak were pooled and concentrated to 37 mg/mL (UV). In sum, the procedure yielded homogenous protein with a purity greater than 95% as judged from Coomassie-stained SDS-PAGE.
References
1. Siegel, J. P. & Puri, R. K. Interleukin-2 toxicity. *J. Clin. Oncol.* 9, 694–704 (1991).
2. Rosenberg, S. A. et al. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. JAMA 271, 907–913 (1994).
3. Klapper, J. A. et al. High-dose interleukin-2 for the treatment of metastatic renal cell carcinoma: a retrospective analysis of response and survival in patients treated in the surgery branch at the National Cancer Institute between 1986 and 2002. *Cancer* 113, 293–301 (2008).
4. Rosenstein, M., Etttinghausen, S. E. & Rosenberg, S. A. Extravasation of intravascular fluid mediated by the systemic administration of recombinant interleukin 2. *J. Immunol.* 137, 1735–1742 (1986).
5. Krieg, C., Létourneau, S., Pantaleo, G. & Boyman, O. Improved IL-2 immunotherapy by selective stimulation of IL-2 receptors on lymphocytes and endothelial cells. *Proc Natl Acad Sci. USA* 107, 11906–11911 (2010).
6. Boymann, O. & Sprent, J. The role of interleukin-2 during homeostasis and activation of the immune system. *Nat. Rev. Immunol.* 12, 180–190 (2012).
7. Setoguchi, R., Hori, S., Takahashi, T. & Sakaguchi, S. Homeostatic maintenance of natural Foxp3+ CD25+ CD4+ regulatory T cells by interleukin (IL)-2 and induction of autoimmune disease by IL-2 neutralization. *J. Exp. Med.* 201, 723–735 (2005).
8. Toomer, K. H. & Malek, T. R. Cytokine signaling in the development and homeostasis of regulatory T cells. *Cold Spring Harb. Perspect. Biol.* 10, a028597 (2018).
9. Van Gool, F. et al. Interleukin-5-producing group 2 innate lymphoid cells control eosinophilia induced by interleukin-2 therapy. *Blood* 124, 3572–3576 (2014).
10. Boyman, O. & Arenas-Ramirez, N. Development of a novel class of interleukin-2 immunotherapies for metastatic cancer. *Swiss Med. Wkly* 149, w14697 (2019).
11. Zhang, Y. et al. A semi-synthetic organism that stores and retrieves increased genetic information. *Nature* 551, 644–647 (2017).
12. Nguyen, D. P. et al. Genetic encoding and labeling of aliphatic azides and alkynes in recombinant proteins via a pyrrolonyl-tRNA Synthetase/tRNA (CUA) pair and click chemistry. *J. Am. Chem. Soc.* 131, 8720–8721 (2009).
13. Kohl, H. C., Finn, M. G. & Sharpless, K. B. Click chemistry: diverse chemical function from a few good reactions. *Angew. Chem. Int. Ed. Engl.* 40, 2004–2021 (2001).
14. Stauber, D. J., Debler, E. W., Horton, P. A., Smith, K. A. & Wilson, I. A. Crystal structure of the IL-2 signaling complex: paradigm for a heterotrimeric cytokine receptor. *Proc. Natl Acad. Sci. USA* 103, 2788–2793 (2006).
15. Wang, X., Rickert, M. & Garcia, K. C. Structure of the quaternary complex of interleukin-2 with its alpha, beta and gammac receptors. *Science* 310, 1159–1163 (2005).
16. Kubetzko, S., Sarkar, C. A. & Pluckthun, A. Protein PEGylation decreases observed target association rates via a dual blocking mechanism. *Mol. Pharm.* 68, 1439–1454 (2005).
17. Boerstoel, N., Lee, T. & Hui, H. in Comprehensive Guide to Toxicology in Preclinical Drug Development (ed. Faqi, A.) 1st edn., 69–86 (Academic Press, 2013).
18. Byrnes-Blake, K. A. et al. Pharmacokinetics and pharmacodynamics of pegylated interferon lambda-1 in cynomolgus monkeys. *J. Interferon Cytokine Res.* 32, 198–206 (2012).
19. Foureau, D. M. et al. Sequential immune monitoring in patients with melanoma and renal cell carcinoma treated with high-dose interleukin-2: immune patterns and correlation with outcome. *Cancer Immunol. Immunother.* 63, 1329–1340 (2014).
20. Mishra, P., Nayak, B. & Dey, R. K. PEGylation in anti-cancer therapy: an overview. *Asian J. Pharm. Sci.* 11, 337–348 (2016).
21. Arranz-Gibert, P., Vanderschuren, K. & Isaacs, F. J. Next-generation genetic code expansion. *Curr. Opin. Chem. Biol.* 46, 203–211 (2018).
22. Rosenberg, A. S. & Worobec, A. A risk-based approach to immunogenicity concerns of therapeutic protein products. *BioPharm. Int.* 17, 34–42 (2004).
23. Fischer, E. C. et al. New codons for efficient production of unnatural proteins in a semisynthetic organism. *Nat. Chem. Biol.* 16, 570–576 (2020).

Acknowledgements
We thank Lauren Baker Willard for editorial improvements, Garima Tiwari, Christian Engel and Gerhard Hessler for assistance with structure alignments and RMSD calculations, Floyd Rombesberg, Carlo Botton and John Reed for helpful comments on the manuscript.

Author contributions
J.L.P., C.E.C. and M.E.M. conceived of the project. J.L.P. and M.E.M. led the project. J.L.P., C.E.C., L.M., N.V.A., L.K.K., I.B.J. and M.E.M. designed the experiments. J.L.P., C.E.C., L.M., K.M.S.J.G., H.R.A., M.J.P., R.W.H., Y.P., D.B.C. and N.V.A. generated and processed the data. J.L.P., C.E.C., L.M., H.R.A., D.B.C., L.K.S., L.K.K., N.V.A., I.B.J. and M.E.M. analyzed the data. J.L.P. and M.E.M. drafted the manuscript. All authors edited and approved the manuscript.

Competing interests
The authors declare the following competing interests: All authors are current or previous employees of Synthorx, Inc., a Sanofi company. Synthorx, a Sanofi Company, Inc. holds patents related to both the technology and pegylated IL-2 molecules presented herein, on which J.L.P., C.E.C. and M.E.M. are listed as inventors.

Additional information
Supplementary information The online version contains supplementary material available at https://doi.org/10.1038/s41467-021-24987-9.

Correspondence and requests for materials should be addressed to J.L.P. or M.E.M.

Peer review information Nature Communications thanks the anonymous reviewer(s) for their contribution to the peer review of this work.

Reprints and permission information is available at http://www.nature.com/reprints

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

© The Author(s) 2021